Boehringer Ingelheim International Gmbh

Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.

Centrexion Therapeutics Corporation

Boehringer Ingelheim Pharma Gmbh & Co Kg

Alkahest, Inc.

Marco Santagostino

Philipp Lustenberger

Klaus Rudolf

Dirk Stenkamp

Stephan Georg Mueller

Henri Doods

Gerhard Schaenzle

Kirsten Arndt

Fabio Paleari

Christoph Hoenke

Thomas Trieselmann

Riccardo Giovannini

Kai Gerlach

Sara Frattini

Stefan Scheuerer

Heiner Ebel

Rocco Mazzaferro

Christofer Siegfried Tautermann

Alexander Dreyer

Piero Melloni

Ingo Konetzki

Markus Frank

Thierry Bouyssou

Andreas Schnapp

Alberto Cerri

Markus Ostermeier

Ulrike Werthmann

Guenther Huchler

Thorsten Pachur

Uwe Stertz

Manuel Henry

Juergen Daeubler

Hans Haeberle

Thomas Trebing

Stephan Kling

Matthias Eckhardt

Leo Thomas

Georg Dahmann

Gerald Juergen Roth

Marco Frigerio

Holger Wagner

Patrizia Ferrari

Thorsten Lehmann-Lintz

Tobias Wunberg

Werner Rall

Rainer Walter

Anke Baum

Juergen Ramharter

Heinz Stadtmueller

Mauro Gobbini

Rainer Soyka

Matthew Russell Netherton

Marcus Schindler

Adil Duran

Juergen Schnaubelt

Christiane Kofink

Bradford S Hamilton

Ralf R H Lotz

Thomas Krueger

Marco Torri

Dorothea Ingrid Rudolph

Annika Gille

Sergio De Munari

Stefan Goepper

Jean-Nicolas Desrosiers

Marco Hans Hofmann

Simona Sputore

Michael Gmachl

Giorgio Fedrizzi

Julian Wippich

Michael Pangerl

Phillip Lustenberger

Fabio Savarese

Guanghua Lu

Rudlof Klaus

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

CCR2 receptor antagonists and uses thereof

The present invention encompasses compounds of formula (1) wherein the groups Rto R, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors

The application includes a description of novel intermediates, of new manufacturing steps resulting in a novel and improved process for producing the intermediates and the final compounds, i.e., 6-alkynyl-pyridine derivatives. The intermediates of the invention are useful to produce 6-alkynyl-pyridine derivatives, which compounds are useful for the treatment of cancer.

Process for the manufacture of 6-alkynyl-pyridine derivatives

This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.

Co-crystals and salts of CCR3-inhibitors

The present invention relates to compounds of formula I wherein Rdenotes F or CF, Rdenotes H or C-alkyl and Z denotes a leaving group or an optionally substituted or protected hydroxyl group, suitable as intermediates in the synthesis of indanyloxydihydrobenzofuranylacetic acids, which are GPR40 agonists, to a process for preparing these intermediates and to the process for preparing the GPR40 agonists making use of an asymmetric catalytic hydrogenation reaction in the presence of a transition metal catalyst and a chiral auxiliary.

Process and intermediates for preparing GPR40 agonists

The present invention relates to a process for the stereoselective preparation of compounds of formulae (1A) and (1B) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.

Stereoselective synthesis of bicyclic heterocycles

This invention concerns a crystalline, enantiopure hydrochloride salt of N-(5-{2-[3-(4,4-diethyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-1,1-dimethyl-propylamino-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methanesulfonamide, preferably of N-(5-{(R)-2-[3-(4,4-diethyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-1,1-dimethyl-propylamino-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methanesulfonamide and its action as a long acting beta-agonist, alone or in combination with one or multiple other active ingredients for the treatment of respiratory diseases.

Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug

The present invention relates to the CGRP antagonists of general formula wherein A, X, D, E, G, M, Q and Rto Rare defined as in claimthe tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Growing community of inventors

Mittelbiberach, Germany

Marco Santagostino